<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48757">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02122328</url>
  </required_header>
  <id_info>
    <org_study_id>HS-09-00680</org_study_id>
    <nct_id>NCT02122328</nct_id>
  </id_info>
  <brief_title>Sequential vs. Standard Laser Treatment of Twin-twin Transfusion Syndrome</brief_title>
  <official_title>USFetus Randomized Clinical Trial: Sequential vs. Standard Laser Treatment of Twin-twin Transfusion Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that treatment of twin-twin transfusion syndrome (TTTS) using
      sequential laser photocoagulation of communicating vessels (SQLPCV) over the predominant
      method, selective laser photocoagulation of communicating vessels (SLPCV), may provide
      vascular stability to the donor fetus. The primary objective is to evaluate the perinatal
      outcome, specifically, donor intrauterine survival of TTTS managed by SQLPCV vs. SLPCV in a
      prospective, randomized trial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>To compare donor intrauterine survival (alive at birth) for those undergoing SQLPCV vs. SLPCV.</measure>
    <time_frame>Birth</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>A comparison of donor survival at birth will be made between subjects assigned to the sequential (SQLPCV) procedure versus those assigned to the selective (SLPCV) procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surgical complications</measure>
    <time_frame>21 post-operative days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Fetal/neonatal/infant outcomes</measure>
    <time_frame>Birth to 6 months of life</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">542</enrollment>
  <condition>Twin Twin Transfusion Syndrome</condition>
  <arm_group>
    <arm_group_label>Selective procedure</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Selective laser photocoagulation of communicating vessels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequential procedure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sequential laser photocoagulation of communicating vessels</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sequential laser photocoagulation of communicating vessels.</intervention_name>
    <arm_group_label>Sequential procedure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Selective laser photocoagulation of communicating vessels</intervention_name>
    <arm_group_label>Selective procedure</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gestational age: 16 weeks, 0 days to 26 weeks, 0 days.

          -  Confirmed TTTS patients, who by definition meet the following sonographic criteria:

               -  Single placenta.

               -  Polyhydramnios: maximum vertical pocket ≥ 8 cm in the recipient twin, prior to
                  amniodrainage.

               -  Oligohydramnios: maximum vertical pocket ≤ 2 cm in the donor twin, prior to
                  amniodrainage.

               -  Thin dividing membrane (absence of twin peak sign) or absence of dividing
                  membrane (monoamniotic).

               -  Same gender, if visible.

               -  Quintero Stages 1-4.

          -  Patients choosing laser therapy that have undergone prior therapeutic amniocentesis
             may be included.

          -  Patients with an anterior placenta may be included.

          -  Triplet gestations with two or three fetuses sharing the same placenta may be
             included.

          -  Patients must be able to give written informed consent.

        Exclusion Criteria:

          -  Patients unable or unwilling to participate in the study or to be followed up.

          -  Patients unable to give written informed consent.

          -  Presence of major congenital anomalies that may not warrant surgery.

          -  Known unbalanced chromosomal complement.

          -  Prior intentional septostomy (purposely making a hole in the dividing membrane).

          -  Ruptured membranes.

          -  Chorioamnionitis.

          -  Abnormal intracranial ultrasound findings of either fetus to include, but not limited
             to: intraventricular hemorrhage, porencephalic cysts, hydrocephalus, Dandy-Walker
             syndrome, holoprosencephaly and agenesis of the corpus callosum. Isolated
             ventriculomegaly (atrium 10-19 mm) may or may not be used as exclusion criteria.

          -  Placental abruption.

          -  Active labor.

          -  Patient unwilling to receive blood products.

          -  Recipient twin with a middle cerebral artery peak systolic velocity &gt; 1.5 multiples
             of the median (indicative of fetal anemia).

          -  Any other patient deemed inappropriate for the study by the principal investigator.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramen Chmait, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ramen Chmait, MD</last_name>
    <phone>323-361-6074</phone>
    <email>chmait@usc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Arlyn Llanes, RN</last_name>
    <phone>323-361-6074</phone>
    <email>allanes@usc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hollywood Presbyterian Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramen Chmait, MD</last_name>
      <phone>323-361-6074</phone>
      <email>chmait@usc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Arlyn Llanes, RN</last_name>
      <phone>323-361-6074</phone>
      <email>allanes@usc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ramen Chmait, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 22, 2014</lastchanged_date>
  <firstreceived_date>April 16, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>Ramen Chmait</investigator_full_name>
    <investigator_title>Assistant Professor, Clinical Obstetrics &amp; Gynecology, Pediatrics, and Surgery</investigator_title>
  </responsible_party>
  <keyword>Twin twin transfusion syndrome</keyword>
  <keyword>Sequential laser photocoagulation of communicating vessels</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fetofetal Transfusion</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
